Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CA 102 N

Next Previous
Drug Profile

CA 102 N

Alternative Names: CA102N; HA-Nimesulide; Hyaluronic acid nimesulide-NH2 bioconjugate; Nim-HA Conjugate

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Holy Stone Healthcare
  • Class Adjuvants; Antineoplastics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Calcium channel antagonists; CD44 antigen inhibitors; Cyclo-oxygenase 2 inhibitors; Hyaluronic acid modulators; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Preclinical Bladder cancer; Pancreatic cancer; Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 14 May 2025 Holy Stone Healthcare plans a clinical trial for Adenocarcinoma (unspecified),
  • 10 Mar 2025 CA 102 N is still in phase I development in Colorectal-cancer(Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 10 Mar 2025 Phase-II clinical trials in Colorectal cancer (Metastatic disease) (IV) (Holy Stone Healthcare, March 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top